Objective: To investigate the susceptibilities to and consequences of HIV-1 dual infection.
Introduction
Given the multitude of circulating and unique recombinant forms of HIV-1 [1] , dual infection with two or more distinct viral strains has been relatively frequent since the beginning of the epidemic. Dual infection can be categorized either as interclade, when the two infecting strains originate from different clades, or intraclade otherwise. Dual infection can be further classified as either coinfection, when infection with the second strain occurs before an immune response to the first strain has been mounted, or superinfection, when infection with the second strain occurs after an immune response to the first strain has been mounted [2] .
Although 16 years have passed since the first cases of HIV-1 dual infection were documented [3] [4] [5] [6] [7] [8] [9] , many questions remain about its clinical, virologic, and immunologic correlates. Clinically, dual infection has been associated with accelerated disease progression with a more rapid decline in CD4þ T lymphocytes and a shorter time to AIDS diagnosis [10] . Also, superinfection has been associated with an increase in viral load after superinfection [11] [12] [13] . Most previous reports have been anecdotal, with superinfection identified using population-based sequencing of one HIV coding region within longitudinally collected samples. However, the detection of dual infection may be obscured by recombination when examining only one HIV-1 coding region [14] , or if one of the strains is present at only low or transient levels [15, 16] .
To further investigate dual infection, we performed a casecontrol study among well characterized HIV-infected men who have sex with men (MSM) followed since primary infection. We screened longitudinal samples collected from cohort participants for dual infection with ultra-deep sequencing (UDS) of circulating viral populations in three HIV-1 coding regions. Within this case-control study, we investigated the clinical, virologic, and immunologic correlates associated with the presence of dual infection, including coinfection and superinfection. We report that intraclade subtype B dual infection is often associated with changes in viral load, and that certain HLA haplotypes are likely associated with superinfection. This report also characterizes a variety of virologic outcomes of intraclade dual infection, including complete replacement of one viral strain by the other, transient presence of a second strain, low-level persistence of one strain, and the production of recombinant viral populations. Taken together, these data may be of interest to patients and their healthcare providers concerning the susceptibilities and risks of dual infection.
Methods
The study was approved by UCSD Human Research Protection Program. Written, informed consent was obtained from all participants and guidelines from the US Department of Health and Human Services were followed.
Study participants, demographics and HLA All participants of the San Diego Primary HIV Infection
Program between January 1998 and January 2007 who deferred antiretroviral therapy (ART) for at least the first 6 months, and had at least two blood samples available, were included. All received baseline drug resistance testing (Geneseq; Monogram Biosciences, South San Francisco, California, USA), and estimated duration of infection (EDI) was calculated, per established protocols [16] . HLA data were collected for the HLA A, HLA B, HLA C and HLA DRB1 loci [17] . For participants with HLA B35, four-digit allele resolution was subsequently obtained.
For the case-control design, we matched monoinfected controls to participants who were classified as coinfected or superinfected based on: follow-up more than 6 months, ART naive, men who reported sex with men as their HIV risk factor, ultra-deep sequencing (UDS) or single genome sequencing (SGS) at a time point less than 12 months from last date of follow-up with sequencing in two or more coding regions (including env), and absence of phylogenetic evidence of dual infection (see below). Participants who were not classified as coinfected, superinfected, or monoinfected were assigned to an undetermined infection class. Demographic and clinical data available from these undetermined infection participants were then compared with the cases (coinfected and superinfected) and the controls (monoinfected) to offer some assessment of potential biases.
Sequencing methods
Population-based HIV-1 pol sequences (HXB2 coordinates 2253-3554), SGS of env C2-V3 and pol RT, and UDS of gag p24 (HXB2 coordinates 1366-1619), pol RT (HXB2 coordinates 2708-3242), and env C2-V3 (HXB2 coordinates 6928-7344) were generated [18] from cryostored blood plasma. UDS runs were done on batches of 16 samples physically separated with rubber gaskets on a 454 GS FLX Titanium picoliter plate (454 Life Sciences; Roche, Branford, Connecticut, USA). Read alignment and filtering were performed using a bioinformatics pipeline for the HyPhy software package [19] that selected high-quality UDS reads, generated sample-specific consensus sequences, aligned reads to the consensus, and performed phylogenetic analysis of specific coding regions, as previously described [20] . All HIV-1 infections were subtyped using pol sequences and the SCUEAL tool [21] .
Dual infection screening and confirmation
HIV-1 dual infection was suspected in a sample when the estimated lower 2.5% confidence bound of nucleotide divergence of at least one coding region's SGS and/or UDS reads exceeded 5% for env and 2.5% for pol and gag, and when the phylogenetic structure of that region included two branches separated with bootstrap support above 95% [18] . On the basis of timing of dual infection, participants with dual infection were then classified as coinfected (i.e. two distinct viral populations at baseline) or superinfected (i.e. one distinct viral population at baseline but two distinct populations in a subsequent sample at least 3 months beyond EDI). The algorithm for monoinfection and dual infection determinations is diagrammed in Fig. 1 . Participants who were classified as ambiguous or did not complete full sequencing evaluations were classified as undetermined infection and excluded from the case-control analysis.
Clinical correlates analysis
Blood plasma was collected from participants at a median of 1.1 month intervals [interquartile range (IQR) 0.7-2.1 months], and viral loads were measured at each time point (Amplicor v. 1.5; Roche, Indianapolis, Indiana, USA) with a lower level of detection at 50 HIV-1 RNA copies/ml and CD4 cell counts measured by flow cytometry. To analyze the viral load and CD4 cell count dynamics with dual infection, we transformed viral load (log 10 ) and CD4 cell counts (square root) and plotted these values versus time since EDI for each participant (Suppl Figures 1-4 , http://links.lww.com/QAD/A188). Linear mixedeffects models assessed transformed viral load and CD4 dynamics of each group (monoinfection, coinfection, and superinfection) (nlme package in R). Each group was included as an indicator variable, and both intercepts and slopes were estimated. Each participant with superinfection was examined for structural change in viral load or CD4 cell count dynamics following superinfection using the Chow test [22] . A Kaplan-Meier analysis was performed for CD4 cell count persistence above 400 cells/ml within the monoinfection, coinfection, and superinfection groups, and significance was determined by the Cox proportional hazards model.
Virologic and immunologic correlates analysis
Recombination and selection analysis Recombination breakpoint analysis of complete RT and C2V3 sequence alignments for each sample was performed using Genetic Algorithms for Recombination Detection (GARD) [23] . Since the power of GARD to detect recombination is reduced if many highly similar sequences are present in an alignment, we represented each group of sequences that were all 1.0% or less distant in pol and 2.0% or less distant in env from each other by a single randomly chosen clone. Pair-wise genetic distances were obtained by maximum likelihood under the GTR model of nucleotide substitution [24] . We screened all sequences for each participant/coding region combination for evidence of positive selection using PARRIS [25] , which corrects for possible confounding effects of recombination, using partitions produced by GARD as input.
Epitope mapping
To study the CTL epitopes inside pol and env sequences, we used available clade B HIV-1 CTL epitope maps for pol, RT, and env (http://www.hiv.lanl.gov/content/immunology/). For participants with superinfection, we evaluated SGS generated from baseline samples and samples with detectable superinfection. For participants with coinfection, we evaluated SGS generated from baseline samples. We compared available sequences to CTL maps and predicted all epitopes targeted by CTL based on the two-digit HLA haplotype of each participant. To assess the HLA allele frequencies in the monoinfection, coinfection, and superinfection groups, we used the online Los Alamos HLA Frequency Analysis tool, which reports both P values and q-values (the false discovery rate) (http://www.hiv.lanl.gov/content/immunology/).
Results

Study participants
After screening 110 male, ART-naive participants, 18 were classified as monoinfected (16.4%), 7 as superinfected (0.06%), 4 as coinfected (0.04%) and 81 as undetermined infection (73.6%). The undetermined infection participants were used as a comparison population. To lessen confounding by risk factor, all selected participants reported being MSM as their initial and on-going HIV risk factor. The median age at enrollment was 31 years (range: 19-58 years), and most participants were white (83%). There was no difference in baseline CD4 cell count between the coinfection, superinfection, monoinfection, and undetermined infection groups (Kruskal-Wallis test P ¼ 0.68), but there was a trend for the superinfection group to have a lower baseline viral load (Kruskal-Wallis test P ¼ 0.08) ( Table 1) .
Clinical correlates
Longitudinal viral loads of participants were plotted over 3 years of follow-up for the monoinfection, coinfection, and superinfection groups (Fig. 2a ). The superinfection group had a lower median viral load at baseline (3.38 versus 3.85 and 4.48 log 10 HIV RNA copies/ml), and at 1 year of follow-up the viral load of the superinfection group (median 4.26, IQR 3.78-4.75 log 10 HIV RNA copies/ml) had overtaken that of the monoinfection group (median 3.20, IQR 2.07-4.46 log 10 HIV RNA copies/ml). Compared to the monoinfection group, the superinfection group had a significantly faster viral load increase over time according to the mixed-effects model (P < 0.001). The coinfection group also had a trend for a faster viral load increase over time than the monoinfection group (P ¼ 0.09). These observations were consistent with structural changes in viral load after superinfection using the Chow test ( Fig. 3a) .
To assess the dynamics of CD4 cell counts, longitudinal counts were plotted over 3 years of follow-up ( Fig. 2b) .
Compared to the monoinfection group, neither the coinfection nor the superinfection groups had a significantly faster CD4 cell count decline (P > 0.05), and Kaplan-Meier analysis showed no significant differences in CD4 cell count persistence above 400 cells/ml among the groups (data not shown). Unlike the changes with viral loads, none of the superinfection cases had a significant structural change in CD4 cell count dynamics (P > 0.05, Chow's test) (Fig. 3b) . We also investigated time to the start of ART, and although a higher proportion of superinfected compared to monoinfected participants started ART within the 3-year period (7/7 superinfected versus 11/ 18 monoinfected), the difference was not statistically significant (P ¼ 0.13, Fisher's exact test). Overall, there were no significant differences between the monoinfection, undetermined infection, coinfection, superinfection, and dual infection groups for the initiation of ART during the 3 years (all P > 0.05, Fisher's exact test).
Virologic correlates during dual infection
Similar to previous reports, the ability to detect dual infection was increased by sequencing more than one coding region [14, 26] , and together, UDS and SGS identified coinfection in four and superinfection in seven participants; UDS and SGS agreed on all samples sequenced with both methods. Dual infection was detected in the env C2V3 coding region at at least one time point for all 11 dually infected participants, in eight of eleven dually infected participants in RT, and in two of eight (eight of the eleven were sequenced) in gag p24. Of the seven participants with superinfection, five acquired the second strain during their first year of infection and two during their second year. Two individuals (K6 and K9), previously characterized with dual infection [13] , demonstrated complete replacement of the original strain in RT and C2V3, whereas in the remaining five cases, superinfecting viruses did not completely replace the original population in one or more HIV-1 coding regions (Suppl Table 1 , http://links.lww.com/QAD/A188).
Since HIV-1 can recombine during dual infection [27] , we screened C2V3 and RT sequences generated before and after dual infection for recombination [23] . Significant evidence for recombination was detected in C2V3 for participant P2 (Suppl Table 1 , http:// links.lww.com/QAD/A188) and in RT for two participants (D2 and S1) (P 0.05 Kishino-Hasegawa test [28] ). Representative samples from initial, superinfecting, and recombinant populations of superinfected participant D2 are shown in Suppl Figure 5 , http://links.lww.com/ QAD/A188.
Immunologic correlates
If CTL responses to the initially infecting strain influence resistance to superinfection, then superinfecting strains may display signatures of escape in putative CTL epitopes. For the five superinfection cases that demonstrated incomplete or transient changes in their viral population after superinfection, amino acid differences between the initial and subsequent populations were no more likely to be within putative CTL epitopes than outside CTL epitopes ( Table 2 , permutation test P > 0.05). However, two superinfected participants (K6 and K9) demonstrated complete replacement of the pol and C2V3 coding regions following superinfection. For both of these cases, amino acid residues conferring putative CTL escape ( Table 2) were observed in the later population of the superinfecting virus.
Previous studies have analyzed the association of HLA haplotypes with rates of HIV-1 disease progression. Although such analyses are influenced by many factors, including the ethnic makeup of study populations, HLA haplotypes B27, B57, and B58 have been associated with slower disease progression [29] [30] [31] , and B7 and B35 with faster progression [29, 31, 32] . The timing of CTL epitope recognition during primary HIV-1 infection is also different among the HLA haplotypes [33] . A comparison of HLA frequencies in our study cohort revealed that the superinfection group had trends (Fisher's exact test P value range 0.07-0.11) for higher frequencies of A29, C16, and B35 and lower frequencies of DRB1-11 than the monoinfection group (Suppl Table 2 , http:// links.lww.com/QAD/A188). In comparison, the coinfection group had higher frequencies of A29, C02, C16, B4, B39 and DRB1-08 and lower frequencies of C04 (P value range 0.02-0.18) than the monoinfection group (Suppl Table 2 , http://links.lww.com/QAD/A188). Additionally, the coinfection group was enriched for the presence of the linked A29 and C16 alleles, as compared to the monoinfection group (50 versus 0%), but this was not statistically significant ( Table 1 ). The superinfection group had a trend for a higher frequency of HLA B35. This haplotype is associated with faster HIV disease progression [34] and targets epitopes less frequently during primary infection [33] . When evaluating for the frequency of having at least one copy of HLA B35 instead of its overall frequency, the prevalence of HLA B35 in the superinfection group was greater than in the monoinfection group (71 versus 22%, P ¼ 0.058 twotailed Fisher's exact test, Table 1 ). Similarly, the prevalence of HLA B35 allele was greater than would be expected for a similar population in the US, independent of racial or ethnic group [35, 36] . Interestingly, the two cases of superinfection with complete replacement of the viral populations (K6 and K9) were the only two superinfected participants who lacked HLA B35. As the type (Px or Py) of HLA B35 has been associated with peptide binding specificity and HIV disease progression [34] , we compared those in the superinfection and monoinfection groups for presence of HLA B35 Px or Py using four-digit HLA haplotyping. Although these numbers are very small (three out of five of the monoinfected and two out of five of the superinfected patients had Px B35), we found no difference in the frequency of these types of HLA B35 associated with superinfection.
Discussion
The clinical, virologic, and immunologic correlates of dual infection are poorly understood, largely due to insufficient numbers of patients screened and characterized for dual infection. Understanding these correlates of intraclade dual infection is important because it is likely more common than interclade dual infection, given the propensity of HIV-1 clades to be distributed unevenly throughout the world. For example, over 90% of HIV infections in the US are with subtype B virus [37] , so if an HIV-infected person is exposed to superinfection in the US and superinfection occurs, then it will most likely be an acquisition of a second HIV-1 clade B virus.
The clinical consequences of dual infection are likely influenced by the immune capability and reactivity of the individual, and this study found that dual infection (both superinfection and coinfection) was associated with faster viral load increases than the viral load changes observed in monoinfected controls. Unlike viral load dynamics, CD4 dynamics of the dual infection groups did not differ significantly from those of the monoinfection group. In four out of seven individuals with superinfection, we could detect a significant structural shift in viral load dynamics, indicating that viral load progression frequently but not always changes following superinfection, and that other factors must impact viral load dynamics following superinfection. Interestingly, this superinfection group had lower baseline viral loads than both the coinfection and monoinfection groups, but the significance of this finding remains unclear. One possibility is that lower viral loads during initial infection may not be able to stimulate sufficient CTL or neutralizing antibody responses to protect against superinfection. Another is that the individuals with superinfection may have been initially infected with a less fit strain and became superinfected after exposure to a more fit strain.
As virus-specific CTL immune responses that develop during primary HIV infection are responsible for the earliest control of viral replication [33, [38] [39] [40] [41] [42] and viral set point [43] , we investigated if there was evidence of CTL escape in new variants observed after dual infection. There was no detectable evidence for CTL pressure and viral escape in any of the participants demonstrating transient dual infection. However, potential CTL escape was identified in the two participants who had replaced the two evaluated coding regions (RT and C2V3) completely. Interestingly, the two participants with complete viral replacement were the only ones with superinfection who did not have HLA B35. Overall, this evidence suggests that CTL responses that develop during primary HIV infection may confer some degree of resistance to superinfection unless the host is exposed to a strain containing residues permitting CTL escape. Therefore, a superinfecting strain with CTL escape mutations possesses an immediate selective advantage over the incumbent strain and can quickly replace it. Individuals with HLA haplotypes that mount late or weak responses (e.g. HLA B35) also seem to be more susceptible to superinfection; however, these early observations require evaluation in larger cohort studies.
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controls, the decisions to initiate ART by participants and their healthcare providers varied, which likely limited our ability to evaluate all clinical consequences of dual infection, as well as potentially confounding some results. Although unavoidable in a case-control study design, there could be a bias in selecting the monoinfected controls, as it is possible that these controls do not adequately represent the natural history of HIV-1 monoinfection. The inclusion criteria associated with the 'confirmation' of monoinfection using sequencing methods could cause a systematic selection bias in the selection of the controls, especially since it is impossible to rule out that dual infection never took place among the monoinfection group. The confirmation of dual infection may also be biased towards the detection of those dually infected individuals who have distinct viral populations that comprise a certain level of co-circulation or when the viral population has been completely replaced over time.
Additionally, in the absence of a gold standard method for determination of dual infection, our methods for confirmation of dual infection were used to limit the number of false positives for dual infection due to a laboratory mistake, that is, sample mix-up or contamination. The resulting conservative bias may have limited our number of observed cases and subsequently our power to see an effect. A more liberal set of criteria for confirmation of dual infection would likely impact the results of the clinical progressions of different groups, as well as the HLA analysis. However, our very conservative criteria increase our confidence in the results that were derived.
Despite these limitations, this study represents a rigorous evaluation of HIV-1 intraclade dual infection and identifies many instances of transient dual infection during the first 2 years of initial infection. Transient dual infection seems to occur more often among individuals who develop mature CTL responses later in infection, like those with HLA B35 haplotypes. However, when B35 is not present and there is complete replacement of the viral population during dual infection, dual infection is most often associated with viral genetic differences consistent with CTL escape. This study also identified that both coinfection and superinfection are associated with higher blood plasma viral loads, but faster loss of CD4 T-cell counts was not observed. Although they will need to be confirmed in larger studies, these results suggest that individuals with lower baseline viral loads may be more susceptible to superinfection. Taken together, these data may provide information for patients and their healthcare providers on potential superinfection susceptibilities (e.g. HLA B35 haplotype and low baseline viral load) and clinical consequences of superinfection (e.g. increased viral load) that can be important factors to consider in discussing the risks of repeat exposure to HIV-1 after initial infection.
